Overkilling Withdrawn Drugs: FDA Gives Thorough Reassessment For Do-Not-Compound List
This article was originally published in RPM Report
Executive Summary
In its preparations for the first meeting of the rechartered Pharmacy Compounding Advisory Committee, FDA devoted considerable effort to defending the inclusion of two drugs on a list of products withdrawn for reasons of safety and efficacy (and therefore illegal to compound). FDA is understandably concerned about making an airtight case for future enforcement – but it sure seems like a lot of trouble for what should be the easiest task the agency faces in implementing the compounding law.